Target intelligence / Profile preview

Porin A (PorA) (PorA)

Target
PorA
Molecular classification
Porin, Outer membrane protein, Beta-barrel protein
01

Overview

Porin A (PorA) is a major outer membrane protein of Neisseria meningitidis, particularly prominent in serogroup B strains where it serves as a critical vaccine antigen. Functionally, it acts as a class 1 outer membrane porin, forming a trimeric beta-barrel structure that facilitates the selective transport of cations and small hydrophilic molecules across the bacterial cell wall (UniProt: P05430). In the context of human disease, PorA is a primary target for the host immune system, as antibodies directed against its surface-exposed loops can trigger complement-mediated killing of the bacteria (PubMed: 11553241). This immunogenicity has led to its inclusion in several outer membrane vesicle (OMV) vaccines, such as Bexsero and MeNZB, designed to combat meningococcal meningitis and septicaemia (NCBI: NBK538214). However, the high rate of antigenic variation in the PorA variable regions (VR1 and VR2) poses a significant challenge for broad-spectrum vaccine development, often necessitating the use of multiple PorA variants or the inclusion of more conserved protein antigens (PubMed: 12655005). Consequently, PorA-based interventions are highly effective against specific strains but require ongoing surveillance of circulating meningococcal genotypes to ensure continued efficacy.

Other names
Class 1 outer membrane proteinPorin AMajor outer membrane protein PorAOMV PorAPorA protein
02

Mechanism of action

Acts as a vaccine antigen that induces the production of strain-specific bactericidal antibodies, which mediate complement-dependent killing of Neisseria meningitidis.

03

Biological functions

Ion transportMembrane permeabilityNutrient transportImmune response induction
04

Disease associations

Meningococcal diseaseMeningitisSepsisInfection
05

Safety considerations

Antigenic variation leading to immune escapeStrain-specific protection limitsPotential reactogenicity of outer membrane vesicle (OMV) based delivery systems
06

Interacting drugs

Bexsero (Meningococcal Group B Vaccine)

2 more in the full profile.

07

Biomarkers

Serum bactericidal antibody (SBA) titerPorA-specific IgG levels

Beyond the preview

Go deeper on Porin A (PorA) (PorA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porin A (PorA) (PorA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call